Government policies are also driving up labour costs, according to press reports. Local governments have decreed increases of 5–25% in the minimum wage paid by companies operating in their jurisdictions, and are also becoming stricter in enforcing labour, worker safety and environmental laws. New government policies are also making it harder to fire or lay off workers.
The rapid rise in labour costs is a result of economic and demographic factors in China. The rapid growth of the Chinese economy, which grew almost 12% in the first quarter of 2010,1 has made it tougher for companies to attract new staff; according to the Wall Street Journal,1 job vacancy postings in China were up 35% in the first quarter of 2010 compared with the same period last year.The pressures have been particularly extreme in Beijing and the coastal cities, where much of China's industrial base is located, and as such, the cost of living in coastal cities such as Shanghai and Shenzhen are growing rapidly. While companies and the government are looking to make more investments in inland cities, where wage rates are currently cheaper, it is expected that wage increases will even be felt there, thanks to fewer people entering the labour force because of the government's one-child policy.
Good news for bio/pharma
While causing short-term disruption, most observers believe that the improving wages and work conditions, and the appreciating renminbi will create a more sustainable Chinese economy that is driven more by domestic spending and less by volatile exports. This is good news for global bio/pharmaceutical companies because it confirms the assumptions and projections underlying a major strategy undertaken by many industry players: pursuing the growth opportunities in emerging markets. As they have faced declining opportunities in North America and Europe, the global bio/pharmaceutical companies have focused their strategic resources on emerging markets, especially the BRIC countries (Brazil, Russia, India and China), by investing heavily through acquisitions, establishment of R&D and sales organisations, and the in-licensing of products to build their local pipelines. The key underlying assumption for this strategy is that rising incomes and living standards in those countries will trigger greater spending on drugs. According to a projection from industry-watcher IMS Health, drug spending in China will grow 20% over the next 5 years.2